Tirzepatide for weight loss is a once-weekly prescription treatment studied as part of a longer-term plan that also included a reduced-calorie diet and more physical activity. In SURMOUNT-1, researchers enrolled adults without diabetes who had obesity, or overweight plus a weight-related complication. At 72 weeks, mean weight change ranged from −15.0% to −20.9% across the three tirzepatide groups, versus −3.1% with placebo. Those are trial averages, not a forecast for one person. Treatment involves a weekly injection, gradual dose changes directed by a prescriber, and follow-up around response and tolerability.
Who was tirzepatide for weight loss studied in?
The phase 3 SURMOUNT-1 trial enrolled 2,539 adults with a body mass index (BMI) of at least 30, or a BMI of at least 27 plus one or more weight-related complications. Participants with diabetes were excluded. The study lasted 72 weeks and compared three fixed-dose tirzepatide groups with placebo.
Those were trial entry criteria, not Promise's eligibility rules and not a checklist that guarantees a prescription. They tell us which population produced the headline evidence. They do not settle whether the medication fits an individual medical history, current medication list, pregnancy plans, or treatment goals.
The SURMOUNT-1 report in the New England Journal of Medicine also makes an important point about context: tirzepatide was studied as an adjunct to lifestyle intervention, not as an injection tested in isolation.
What the headline result means
At week 72, the trial reported mean body-weight changes of −15.0%, −19.5%, and −20.9% in the 5 mg, 10 mg, and 15 mg groups, respectively, compared with −3.1% in the placebo group. The detailed tirzepatide weight-loss results page follows the numbers over time; the useful point here is that the largest mean change came after more than a year of structured treatment.
An average is not a promise. Some participants lost more, some less, and some discontinued treatment. The trial also included a 20-week dose-escalation period, so its endpoint should not be read as the result of starting at a maintenance dose or as a short-term target.
Zepbound and Mounjaro have different labels
Zepbound and Mounjaro are brand products that both contain tirzepatide, but their U.S. labels are different. As of September 2026, Zepbound—not compounded tirzepatide—is FDA-approved for chronic weight management: its current FDA label covers reducing excess body weight and maintaining weight reduction long term in adults with obesity, or adults with overweight and at least one related condition. The label also covers moderate-to-severe obstructive sleep apnea in adults with obesity.
The current Mounjaro label includes a glycemic-control indication for adults and children age 10 or older with type 2 diabetes and a cardiovascular-risk indication for adults with type 2 diabetes who are at high risk of major cardiovascular events. A brand name therefore signals an indication and a reviewed finished product, not a different molecule.
Tirzepatide through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA explains that compounded drugs do not undergo its premarket review for safety, effectiveness, or quality and may be appropriate when a patient's medical need cannot be met by an approved drug. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
What dual GIP and GLP-1 activity means
Tirzepatide activates receptors for two gut hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The current Zepbound label describes effects on appetite and calorie intake, along with delayed gastric emptying. That dual-receptor design is the defining pharmacology; it is not a guarantee of a particular result.
For the full biology, see how tirzepatide works. The separate tirzepatide versus semaglutide comparison addresses how a dual GIP/GLP-1 medicine differs from a GLP-1-only medicine without turning this article into a contest between the two.
What weekly treatment actually involves
Published tirzepatide protocols use a subcutaneous injection once each week. They begin with an initiation period and increase gradually rather than jumping directly to a maintenance level. The prescriber sets the actual dose and timing from the prescribed formulation, then weighs response and tolerability before any change.
Week to week, the work is less dramatic than the headline result. It means keeping a consistent injection routine, noticing changes in appetite and meal size, and reporting symptoms or medication changes. Follow-up matters because the most useful plan is not necessarily the highest dose; it is the plan a person can tolerate and sustain under clinical supervision.
The formulation also changes the practical details. Brand pens and vials have their own instructions, while a compounded vial follows the pharmacy label and the prescriber's directions. Those formats should not be treated as interchangeable instructions.
Why diet and activity remain part of the plan
Every SURMOUNT-1 group received lifestyle intervention. The 2026 Zepbound label describes a reduced-calorie diet and physical-activity counseling that continued throughout the 72-week weight study. That design matters: the trial measured medication plus a structured foundation, not medication in place of food and movement.
Diet and activity also give the clinical team something concrete to adjust when appetite changes. The goal is not punishment or perfect adherence. It is enough nutrition, a workable energy deficit where appropriate, and movement that can continue beyond the early months of treatment.
What happens when tirzepatide stops
Stopping can change the trajectory. In the randomized SURMOUNT-4 withdrawal trial, participants first received tirzepatide for 36 weeks and lost 20.9% on average. Over the next 52 weeks, those switched to placebo regained 14.0% from the point of randomization, while those continuing tirzepatide lost another 5.5% (JAMA, 2024).
That does not mean every person regains the same amount. It does show why tirzepatide is framed as long-term management rather than a brief course with a permanent endpoint. The guide to what happens after stopping tirzepatide covers the maintenance conversation in depth.
Where the clinical decision sits
A licensed provider reviews every request and not everyone qualifies. If tirzepatide is prescribed, that provider sets the formulation, dose plan, monitoring, and follow-up rather than applying the SURMOUNT-1 criteria as an automatic rule.
The most useful intake is a complete one: medical history, current prescriptions and supplements, prior weight-management treatment, and relevant symptoms all affect the decision. Tirzepatide can be one part of care, but the accountability comes from having a clinician decide whether it belongs in the plan and remain available as the plan changes.